ClinicalTrials.gov
public full text
Public Domain
Somatostatin in Living Donor Liver Transplantation
Aim of the study is to investigate the safety and the efficacy of somatostatin as liver inflow modulator in patients with end-stage liver disease (ESLD) and clinically significant portal hypertension (CSPH) undergoing Adult-to-Adult living donor liver transplantation (A2ALDLT).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Mortality, Morbidity and Risk Factors of Liver Retransplantation#847891
- Post-Operative Use of Salt Poor Albumin Solution in Resuscitation of Orthotopic Liver Transplant#884024
- Efficacy and Safety of Combination Ambrisentan and Tadalafil in Patients With Portopulmonary Hypertension#1213392
- Evaluation of available scoring systems in liver transplantation for severe acute-on-chronic liver failure (ACLF)#1000628
- Plasmatic Factor V as a Predictor of Graft Dysfunction After Liver Transplantation#804449
Record · ID 1385283
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive